Children with MS had fewer relapses on pills or infusions

Credibility

Interest

Share:1 min read

Key Takeaway

Children switching from MS shots to pills or infusions had fewer relapses than children switching to different shots.

What They Found

Researchers studied children who changed MS drugs after starting with shots. Of those children, 93 switched to different shots, 76 switched to pills, and 43 switched to infusions. Children who switched to pills had fewer relapses than those who switched to different shots. Children who switched to infusions also had fewer relapses. The infusion group was more likely to have active areas of damage on brain scans before switching.

Who Should Care and Why

The study followed children with MS or a first MS-like attack at clinics in the United States. Most of the children had MS. All had started treatment with shots before changing drugs. The findings compare what happened after switches to different shots, pills, or infusions. They address relapse rates, not the long-term safety of these drugs.

Important Considerations

You should know this was an observational study of 212 children, not a trial that assigned drugs. The groups differed before switching, which makes it harder to know whether the drug switch caused the difference. The researchers said long-term safety data are still needed.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates MS Progression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News